Elite Pharmaceuticals Inc (ELTP)

[Chasing]

the total market size of the pipeline products that we are co-developing with SunGen is $6 billion.

Our SequestOx will constitute in revenues less than 1% of the products we are working on today.

SequestOx instant release has an IMS Data for all of the generics in the market of about $400 million to $500 million.
Percocet is $700 million.
Norco is $700 million.
OxyContin is $2.5 billion.

Even though SequestOx is a very important product for us, because it was the very first one we started with that validated our technology that we ran the HAL studies on, that we are very excited about. It truly is today. This is not four years ago now. Today it is a small percentage of the product that we are working on.

ELTP's prospects diminished greatly with the SequestOx PDUFA.

PROSPECTS NOT SO GREATLY DIMINISHED AFTERALL